In this study, published recently in the journal Alzheimer's & Dementia, the researchers from the ABOARD and MIRIADE projects found that the majority of participants were in favour of blood-based biomarker testing for Alzheimer’s disease (AD). They were able to identify perceived benefits and hurdles, which they say will play an important role in increasing acceptance and smoothen implementation of blood tests in the future. Read the full article here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10870798/